P
Peter Chin
Researcher at Genentech
Publications - 60
Citations - 3890
Peter Chin is an academic researcher from Genentech. The author has contributed to research in topics: Ocrelizumab & Fingolimod. The author has an hindex of 16, co-authored 57 publications receiving 3031 citations. Previous affiliations of Peter Chin include Novartis.
Papers
More filters
Journal ArticleDOI
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalban,Stephen L. Hauser,Ludwig Kappos,Douglas L. Arnold,Amit Bar-Or,Giancarlo Comi,Jérôme De Seze,Gavin Giovannoni,Hans-Peter Hartung,Bernhard Hemmer,Fred D. Lublin,Kottil Rammohan,Krzysztof Selmaj,Anthony Traboulsee,Annette Sauter,Donna Masterman,Paulo Fontoura,Shibeshih Belachew,Hideki Garren,N. Mairon,Peter Chin,Jerry S. Wolinsky +21 more
TL;DR: Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo; there was no clinically significant difference between groups in the rates of serious adverse events and serious infections.
Journal ArticleDOI
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L. Hauser,Amit Bar-Or,Giancarlo Comi,Gavin Giovannoni,Hans Peter Hartung,Bernhard Hemmer,Fred D. Lublin,Xavier Montalban,Kottil Rammohan,Krzysztof Selmaj,A. Traboulsee,Jerry S. Wolinsky,Douglas L. Arnold,Gaelle Klingelschmitt,Donna Masterman,Paulo Fontoura,Shibeshih Belachew,Peter Chin,N. Mairon,Hideki Garren,Ludwig Kappos +20 more
TL;DR: Among patients with relapsing multiple sclerosis, ocrelizumab was associated with lower rates of disease activity and progression than interferon beta‐1a over a period of 96 weeks.
Journal ArticleDOI
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial†
Kathleen Hawker,Paul O'Connor,Mark S. Freedman,Peter A. Calabresi,Jack P. Antel,Jack H. Simon,Stephen L. Hauser,Emmanuelle Waubant,Timothy Vollmer,Hillel Panitch,Jiameng Zhang,Peter Chin,Craig H. Smith +12 more
TL;DR: Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS).
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study
Xavier Montalban,B. Hemmer,Kottil Rammohan,Gavin Giovannoni,J. de Seze,Amit Bar-Or,Douglas L. Arnold,Annette Sauter,Algirdas Kakarieka,Donna Masterman,Peter Chin,Hideki Garren,Jerry S. Wolinsky,Oratorio Clin Investigators +13 more
Patent
Methods for treating progressive multiple sclerosis
Craig H. Smith,Peter Chin +1 more
TL;DR: In this paper, the authors present methods for treating progressive multiple sclerosis (MS) in a patient and an article of manufacture with instructions for such use, and an application of such methods is described.